Related Experiment Video
Updated: Sep 26, 2026
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
CD45 protein-tyrosine phosphatase inhibitor development
1Laboratory of Medicinal Chemistry Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, PO Box B, Bldg 376 Boyles St, Frederick, MD 21702-1201, USA.
Abstract:
The protein-tyrosine phosphatase (PTP) CD45 serves both positive and negative signaling elements by dephosphorylating regulatory pTyr residues on Src-family protein-tyrosine kinases. Although its physiological participation in immune function makes it an important point of intervention for treatment of a variety of inflammatory and immune disorders, comparatively little has been reported on development of CD45 inhibitors. Frequently, when inhibitory data against CD45 is reported, the data has been generated secondarily to other target PTPs. The focus of the current review is to summarize the types of structures that have been found to inhibit CD45, even in cases the compounds themselves were designed as antagonists of other PTPs. The review's organization begins with generic broad spectrum PTP inhibitors and progresses from peptide-based inhibitors and small molecule peptide mimetics to inhibitors that have resulted from screening hits. Although potent and moderately selective CD45 inhibitors have been reported, no single dominant theme has yet emerged in the design of these CD45-directed agents.
Insights
This review summarizes CD45 inhibitors, crucial for immune disorders. Despite potent agents, a unified design strategy for CD45 inhibitors remains elusive, highlighting ongoing research needs.
Area of Science:
- Immunology
- Biochemistry
- Pharmacology
Background:
- CD45 (protein-tyrosine phosphatase) regulates immune cell signaling by dephosphorylating Src-family kinases.
- Dysregulation of CD45 activity is implicated in inflammatory and immune disorders, making it a therapeutic target.
- Development of specific CD45 inhibitors is limited, with much existing data derived from studies on other PTPs.
Purpose of the Study:
- To review and categorize known structural inhibitors of CD45.
- To consolidate information on CD45-targeting compounds, including those initially designed for other PTPs.
- To identify trends and gaps in the development of CD45 inhibitors.
Main Methods:
- Literature review focusing on published studies reporting CD45 inhibition.
- Categorization of inhibitors based on structural class: broad-spectrum PTP inhibitors, peptide-based inhibitors, peptide mimetics, and screening hits.
- Analysis of inhibitor potency and selectivity data.
Main Results:
- A diverse range of chemical structures have demonstrated inhibitory activity against CD45.
- Inhibitors span from broad-spectrum agents to more specific peptide mimetics and screening-derived compounds.
- Potent and moderately selective CD45 inhibitors exist, but no single dominant structural motif has emerged.
Conclusions:
- CD45 inhibitors represent a promising therapeutic avenue for immune and inflammatory diseases.
- The structural diversity of CD45 inhibitors underscores the complexity of targeting this enzyme.
- Further research is needed to establish a clear design paradigm for developing highly selective and effective CD45 inhibitors.
